on the analgesic ef®cacy of intrathecal morphine and clonidine after coronary artery bypass graft (CABG) and would like to raise some points. First, the consumption of patient-controlled anaesthesia (PCA) morphine in the ®rst 24 h after surgery is higher in the group where morphine 4 mg kg ±1 was given intrathecally (40.5 mg) than in the control group (37 mg). In contrast, for the patients who received morphine with clonidine 1 mg intrathecally, the PCA requirement was markedly reduced (only 7 mg). This implies that intrathecal morphine has nothing to offer in terms of analgesia in the postoperative period after CABG surgery. Second, patients in the three groups had access to a PCA to deliver i.v. morphine, yet there was wide variation in the degree of pain relief in the three groups. At no point in time did patients in the control group or intrathecal morphine group have a visual analogue scale (VAS) score of zero, unlike the morphine + clonidine group. In the control group, the VAS score was between 20 and 35 mm, which signi®es inadequate pain relief. Could this be attributable to a lower dose of morphine? Whether any rescue analgesic was made available to the patients who had higher VAS scores is another matter of concern. The conclusions of the present study cannot be accepted as accurate, as the higher VAS scores in the control, as well as in the morphine group, at almost all the time intervals do not lead to comparable end points of pain relief.
It was also shown that the intraoperative requirement for sufentanil was signi®cantly less in the morphine + clonidine group than the other two groups. It needs to be clari®ed as to how the dose of sufentanil was determined. Was the anaesthetist administering the drug blinded to the different groups?
An important observation of the study, although not mentioned as a conclusion, is that morphine administered intrathecally in a dose of 4 mg kg ±1 has no effective analgesic role in the intraoperative or the postoperative period. We feel further study is needed before this drug, which is considered the gold standard for analgesic comparisons, is shown in such a poor light.
EditorÐWe thank Dr Singh and colleagues for their comments concerning the PCA morphine consumption in patients who received intrathecal morphine or morphine + clonidine. First of all, there is a misunderstanding about the morphine dose. The mean i.v. morphine dose was not`higher' in the intrathecal morphine group but was statistically comparable with the one administered to the control group. This does not imply that morphine has nothing to offer in terms of analgesia in CABG patients, but that this dose of intrathecal morphine did not allow a decrease in i.v. morphine consumption in the current study.
VAS scores <30 mm are considered to represent adequate pain relief. Although the median values of VAS scores were lower in the intrathecal clonidine + morphine group, median values of VAS scores ranging between 20 and 35 mm do not signify inadequate pain relief, but only that VAS scores were statistically lower in the morphine + clonidine group compared with the control group.
Intraoperative sufentanil administration was lower in the morphine + clonidine group. As noted in our paper, 1 anaesthetists and nurses were blinded to the allocation of patients in the three groups and they adjusted the sufentanil infusion rate to changes in arterial blood pressure and heart rate during CABG surgery. Thus the difference in sufentanil consumption is a valid ®nding, and is supported by numerous other studies reporting an opioid-sparing effect of clonidine. Diplopia after cataract surgery
EditorÐWe were interested to read Gomez-Arnau and colleagues' article on anaesthesia-related diplopia after cataract surgery, 1 and the correspondence by Lanigan and Hammond. 2 Transient diplopia (and very occasionally persistent diplopia) is a recognized postoperative complication of local anaesthetic cataract surgery. The exact aetiology of muscle injury is unknown but could be attributable to direct muscle or nerve trauma, local anaesthetic myotoxicity, periocular haemorrhage, or a combination of these. 3 In our department,~2800 local anaesthetic cataract operations are performed each year under retrobulbar, peribulbar, subTenons' or topical local anaesthesia. These are done with or without hyaluronidase and are administered by junior and senior members of the surgical and anaesthetic teams. From our experience over 10 years, not one case of persistent postoperative diplopia has been seen.
It is true to say that the non-occurrence of an adverse event in a surgical series does not mean it cannot happen. 4 The probability of such adverse events during and after operations that have not yet occurred in a ®nite number of patients (n) can be estimated with Hanley's simple formula. It states that if none of n patients showed the event with which one is concerned, one can be 95% con®dent that the chance of this event is, at most, 3 in n (i.e. 3/n). In other words, the upper 95% con®dence limit of a 0/n rate is~3/ n (for n>30).
5 Therefore, the maximum risk of this complication in our patients would be 3/2800 (0.001%).
It seems, therefore, that the incidence of 0.25% reported by Gomez-Arnau and colleagues, 1 
